about
Allosteric activation of ADAMTS13 by von Willebrand factor.[Determination of the ADAMTS13 antigen and its activity in TTP patients and carriers].ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission.ADAMTS13 in health and disease.Mutation of the H-bond acceptor S119 in the ADAMTS13 metalloprotease domain reduces secretion and substrate turnover in a patient with congenital thrombotic thrombocytopenic purpura.Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus).Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura.Residues Arg568 and Phe592 contribute to an antigenic surface for anti-ADAMTS13 antibodies in the spacer domainInhibition of von Willebrand factor-platelet glycoprotein Ib interaction prevents and reverses symptoms of acute acquired thrombotic thrombocytopenic purpura in baboons.Observational study of corrected count increments after transfusion of platelets treated with riboflavin pathogen reduction technology in additive solutions.Development of monoclonal antibodies that inhibit platelet adhesion or aggregation as potential anti-thrombotic drugs.Linker regions and flexibility around the metalloprotease domain account for conformational activation of ADAMTS-13.Inherited traits affecting platelet function.Multi-step binding of ADAMTS-13 to von Willebrand factor.Platelets at work in primary hemostasis.Local elongation of endothelial cell-anchored von Willebrand factor strings precedes ADAMTS13 protein-mediated proteolysisA Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time.The distal carboxyterminal domains of murine ADAMTS13 influence proteolysis of platelet-decorated VWF strings in vivo.Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub)endothelial VWF from cleavage by ADAMTS13.Nitric oxide levels increase during platelet concentrate production from buffy coats, but not during storage.Oxygen removal during pathogen inactivation with riboflavin and UV light preserves protein function in plasma for transfusion.Paired analysis of plasma proteins and coagulant capacity after treatment with three methods of pathogen reduction.Screening for HLA antibodies in plateletpheresis donors with a history of transfusion or pregnancy.High platelet content can increase storage lesion rates following Intercept pathogen inactivation primarily in platelet concentrates prepared by apheresis.The contribution of von Willebrand factor-GPIbα interactions to persistent aggregate formation in apheresis platelet concentrates.Persistent aggregates in apheresis platelet concentrates are commonly collected from donors with a history of aggregate donation.Riboflavin and amotosalen photochemical treatments of platelet concentrates reduce thrombus formation kinetics in vitro.Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro.Ultraviolet C light pathogen inactivation treatment of platelet concentrates preserves integrin activation but affects thrombus formation kinetics on collagen in vitro.Psoralen and Ultraviolet A Light Treatment Directly Affects Phosphatidylinositol 3-Kinase Signal Transduction by Altering Plasma Membrane Packing.Persistent aggregates in apheresis platelet concentrates.Decreased ADAMTS-13 (A disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure*ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosisBiomolecular Consequences of Platelet Pathogen Inactivation MethodsActive platelet-binding conformation of plasma von Willebrand factor in young women with acute myocardial infarctionADAMTS13's tail taleFactor XI/ADAMTS13 complexes are quantitatively insignificant in human plasmaAlteration of ADAMTS13 antigen levels in patients with idiopathic thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura and systemic lupus erythematosusAggregates in platelet concentratesComparison of three commercially available buffy coat pooling sets for the preparation of platelet concentrates
P50
Q29568910-3036AEF2-413E-430B-A130-72FF6BAB1FE3Q33371656-93762FDC-9038-49D9-BF7E-ED11D845541AQ33378424-770D39D0-5C10-4561-9BB3-4373160A6D7AQ33384900-E86F545D-BBB5-4254-925D-8C18B18C97C7Q33386400-87FA4AD4-7604-4EAD-A82E-06B484C4CE55Q33390150-BA060D3C-EDD9-4A91-89F9-7D82D24D2F8EQ33390171-354061C5-F793-4A9C-8FFD-CDFCCFBCEDC9Q33395978-976167EE-BB30-4DB2-A00F-04F565B9A5A9Q33402641-918A15F5-DD51-4DE6-B341-5A29A75E8107Q33420599-5C563844-8987-42C1-BFAD-3A66F474DA12Q36611910-CEB45FEE-C9CC-49D6-A088-35DBAF43DFACQ36652558-24E04D15-C72E-45F4-8ABE-FDB072CF4A76Q37052328-DFE984A9-E763-4D4F-ADE8-9D10F84E6FB0Q37393329-72C21DB6-8022-46C0-8589-A80A66CD533AQ37865759-C80C6C65-4A76-460A-949A-7E91AF5A45DAQ38743345-70F05F29-E82E-4831-A78A-C696A21B4F01Q38911547-A249C5C9-7FE5-48CC-8333-885853D84BDCQ39669533-7CD71F7C-8577-49F8-9E46-BD97D50B76E2Q42194066-55505AF6-5F27-4292-B2D3-A0080E8D8A17Q45120143-75750324-440A-480D-8119-73E7C008BA66Q46141738-AD6E1816-3EE4-4675-A405-F9547FCEC729Q46379566-8DEC355D-B624-4452-8888-9AB5FBC3207FQ46948508-B2258CCF-5B7E-4917-B691-001F96049351Q47901903-83BFB24C-D915-4CCD-800B-7E066F0C62D5Q48092153-1B9DA41E-606E-4116-AFEA-23B45F141A42Q48119304-26D04019-7E2E-4B3D-821B-B29074C7A467Q49025509-F15F1748-EB7D-4A39-84F7-C88BD00983F4Q49061820-7C99B054-7071-4A05-86CB-FADACF78CA87Q49143801-5738A703-F19C-4BC8-BA89-46BED14C9F8DQ49150858-4D859DF1-3F0F-4BB9-99F8-77732AB57586Q49155089-9250E616-4AB3-4C23-BE33-2832AFACC87EQ58481438-F42E77CC-1667-4C5B-A279-0DC46DDDF2E3Q58481440-CDC6B4B8-EF29-4129-848D-4D005A56105AQ59356555-AC5BFFA3-D30B-4D5D-AAC2-5F499A0BFFF3Q61040506-1B2580E3-11D8-4DDF-9837-110E01B71BCCQ63346655-FE6A5B97-EBD6-4D66-8EA1-C4E6850C385FQ63346658-568D9CAE-F390-48D6-A5AD-247148D4C7BCQ83120438-5B166271-B125-4017-9B13-6888E49FB47CQ85334956-2C5C2653-CEE9-43F7-A764-BB99B98F4349Q88805156-64A301DA-3118-42CC-AF57-07F9FC4D343B
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Hendrik B Feys
@es
Hendrik B Feys
@nl
Hendrik B Feys
@sl
Hendrik B. Feys
@en
type
label
Hendrik B Feys
@es
Hendrik B Feys
@nl
Hendrik B Feys
@sl
Hendrik B. Feys
@en
prefLabel
Hendrik B Feys
@es
Hendrik B Feys
@nl
Hendrik B Feys
@sl
Hendrik B. Feys
@en
P106
P108
P1153
12803075000
P21
P31
P496
0000-0003-0052-8852
P569
2000-01-01T00:00:00Z